Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.68 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.46 |
| ▸ | ROS1 | P08922 | 2/20 | 0.46 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25002440 | 0.89 | EGFR (0.56) | EGFRBTKALKROS1CDK19 | |
| SCHEMBL25001489 | 0.89 | EGFR (0.84) | EGFRBTKALKCDK19LRRK2 | |
| SCHEMBL25001558 | 0.88 | EGFR (0.55) | EGFRBTKALKCDK19MAP4K1 | |
| SCHEMBL27091346 | 0.88 | EGFR (0.64) | EGFRBTKALKCDK19LRRK2 | |
| SCHEMBL27091519 | 0.86 | EGFR (0.67) | EGFRBTKALK | |
| SCHEMBL27091454 | 0.85 | EGFR (0.74) | EGFRBTKALKCDK19LRRK2 | |
| SCHEMBL27091391 | 0.85 | EGFR (0.75) | EGFRBTKALKLRRK2 | |
| SCHEMBL25001487 | 0.84 | EGFR (0.76) | EGFRBTKALKROS1CDK19 | |
| SCHEMBL25001952 | 0.84 | EGFR (0.73) | EGFRBTKALKLRRK2 | |
| SCHEMBL23302517 | 0.83 | EGFR (0.87) | EGFRBTKALKROS1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112538072-B | Aminopyrimidine EGFR inhibitors | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-112538072-A | Novel aminopyrimidine EGFR (epidermal growth factor receptor) inhibitor | 齐鲁制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | EGFR 1/4885BTK 265/4885ALK 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.